ACE2 and COVID-19: The prophylaxis concept gains significance when considering the potential biosafety threat of viruses such as NeoCoV (107), which uses an angiotensin-converting enzyme 2 (ACE2) for entry into humans similar to the SARS-CoV2 virus, as the implications of immune-modulation cover sepsis and sepsis-like reactions that occur in viral infections such as COVID-19.